Evaxion Wins 2026 Prix Galien UK Award for AI-Immunology Digital Health Platform
TipRanks (Fri, 12-Jun 6:31 AM ET)
Evaxion receives Prix Galien UK Award for Best digital health solution
Globe Newswire (Fri, 12-Jun 3:00 AM ET)
Evaxion Unveils Promising Preclinical Data for AI-Designed AML Vaccine EVX-04
TipRanks (Thu, 11-Jun 6:28 AM ET)
Globe Newswire (Thu, 11-Jun 2:00 AM ET)
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?
Seeking Alpha News (Wed, 10-Jun 3:19 PM ET)
Globe Newswire (Tue, 12-May 9:30 AM ET)
Evaxion announces business update and first quarter 2026 financial results
Globe Newswire (Thu, 7-May 7:30 AM ET)
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
Globe Newswire (Mon, 4-May 8:00 AM ET)
Evaxion promotes Birgitte Rn to joint role of Chief Scientific and Chief Operating Officer
Globe Newswire (Mon, 27-Apr 8:00 AM ET)
Globe Newswire (Fri, 17-Apr 3:10 PM ET)
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Evaxion A/S - American Depositary Share trades on the NASDAQ stock market under the symbol EVAX.
As of June 12, 2026, EVAX stock price climbed to $3.64 with 57,060 million shares trading.
EVAX has a beta of 1.58, meaning it tends to be more sensitive to market movements. EVAX has a correlation of 0.05 to the broad based SPY ETF.
EVAX has a market cap of $30.36 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, EVAX traded as high as $345.53 and as low as $1.20.
EVAX has underperformed the market in the last year with a price return of +22.6% while the SPY ETF gained +24.1%. EVAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -12.9% and -9.0%, respectively, while the SPY returned +11.6% and -1.9%, respectively.
EVAX support price is $3.42 and resistance is $3.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVAX shares will trade within this expected range on the day.